Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

Background and purpose Significant effects on clinical/neuroradiological disease activity have been reported in patients with relapsing–remitting multiple sclerosis treated with delayed‐release dimethyl fumarate ( DMF ) in phase III DEFINE / CONFIRM trials. We conducted a post hoc analysis of integrated data from DEFINE / CONFIRM to evaluate the effect of DMF on achieving no evidence of disease activity ( NEDA ) in patients with...